Val J. Watts

Molecular mechanisms for heterologous sensitization of adenylate cyclase.

Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells.

Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.

A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases.

Sensitization of adenylate cyclase: a general mechanism of neuroadaptation to persistent activation of Galpha(i/o)-coupled receptors?

Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation.

Sensitization of adenylate cyclase by short-term activation of 5-HT1A receptors.

Novel regulatory properties of human type 9 adenylate cyclase.

Differentiation-induced alterations in cyclic AMP signaling in the Cath.a differentiated (CAD) neuronal cell line.

Sexual experience alters D1 receptor-mediated cyclic AMP production in the nucleus accumbens of female Syrian hamsters.

Using molecular tools to dissect the role of Galphas in sensitization of AC1.

Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells.

Activation of a novel PKC isoform synergistically enhances D2L dopamine receptor-mediated sensitization of adenylate cyclase type 6.

Galphaq potentiation of adenylate cyclase type 9 activity through a Ca2+/calmodulin-dependent pathway.

Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation.

Dexras1 blocks receptor-mediated heterologous sensitization of adenylyl cyclase 1.

Sensitization of adenylate cyclase by Galpha i/o-coupled receptors.

Structure of Galpha(i1) bound to a GDP-selective peptide provides insight into guanine nucleotide exchange.

A bifunctional Galphai/Galphas modulatory peptide that attenuates adenylyl cyclase activity.

D2 dopamine receptor-induced sensitization of adenylyl cyclase type 1 is G alpha(s) independent.

Dexamethasone-induced Ras protein 1 negatively regulates protein kinase C delta: implications for adenylyl cyclase 2 signaling.

Regulatory properties of adenylate cyclases type 5 and 6: A progress report.

Repeated quinpirole treatments produce neurochemical sensitization and associated behavioral changes in female hamsters.

WAY-100635 is a potent dopamine D4 receptor agonist.

trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.

Adenylyl cyclase isoforms as novel therapeutic targets: an exciting example of excitotoxicity neuroprotection.

Adenylyl cyclase 5: a new clue in the search for the "fountain of youth"?

Ligand-dependent oligomerization of dopamine D(2) and adenosine A(2A) receptors in living neuronal cells.

A point mutation to Galphai selectively blocks GoLoco motif binding: direct evidence for Galpha.GoLoco complexes in mitotic spindle dynamics.

Adenosine A(2A) receptors assemble into higher-order oligomers at the plasma membrane.

Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.

Fluorescent and bioluminescent protein-fragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling.

The intracellular II-III loops of Cav1.2 and Cav1.3 uncouple L-type voltage-gated Ca2+ channels from glucagon-like peptide-1 potentiation of insulin secretion in INS-1 cells via displacement from lipid rafts.

Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers.

Visualization of G protein-coupled receptor (GPCR) interactions in living cells using bimolecular fluorescence complementation (BiFC).

Fluorescent protein complementation assays: new tools to study G protein-coupled receptor oligomerization and GPCR-mediated signaling.

Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists.

Molecular and pharmacological characterization of two D(1)-like dopamine receptors in the Lyme disease vector, Ixodes scapularis.

Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues.

Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.

Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.

Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease.

A "genome-to-lead" approach for insecticide discovery: pharmacological characterization and screening of Aedes aegypti D(1)-like dopamine receptors.

Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists.

Dopamine D(2) Receptor-Mediated Heterologous Sensitization of AC5 Requires Signalosome Assembly.

Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand.

Discovery of antagonists of tick dopamine receptors via chemical library screening and comparative pharmacological analyses.

Bimolecular fluorescence complementation analysis of G protein-coupled receptor dimerization in living cells.

Differential effects of AGS3 expression on D(2L) dopamine receptor-mediated adenylyl cyclase signaling.

Cell-type specific increases in female hamster nucleus accumbens spine density following female sexual experience.

Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor.